中源协和：公司VUM02注射液治疗特发性肺纤维化及治疗急性移植物抗宿主病获得美国FDA授予的孤儿药资格认定

Core Viewpoint - Zhongyuan Qihe has received orphan drug designation from the FDA for its VUM02 injection, which is intended for the treatment of idiopathic pulmonary fibrosis and acute graft-versus-host disease [2] Group 1 - The company is actively exploring and planning international collaborations in accordance with domestic and international pharmaceutical regulations [2] - The focus is on diversifying cooperation models to advance the development of its cell therapy business [2]